{"database": "lobbying", "table": "lobbying_activities", "is_view": false, "human_description_en": "where filing_period = \"second_quarter\", filing_year = 2014 and issue_code = \"PHA\" sorted by filing_year descending", "rows": [[1545240, "2b0ccfe9-2ffa-4dd0-a2fb-259fd67d3ace", "Q2", "INDEPENDENT PHARMACY COOPERATIVE", 313098, "INDEPENDENT PHARMACY COOPERATIVE", 2014, "second_quarter", "PHA", "CMS Proposed Program Changes for Medicare Advantage and Prescription Drug Benefit Program for Conract Year 2015-Support Changes to Preferred Networks, Mail Order Prescriptions and MTM Services.", "Centers For Medicare and Medicaid Services (CMS),SENATE", null, null, 0, 0, "2014-06-13T11:58:48.320000-04:00"], [1545762, "66b00f97-0826-4463-aa77-ac3d0a6c8b2d", "Q2", "CYBER SECURITY RESEARCH CONSULTANTS, LLC", 91694, "PDFRAZER CONSULTING INC CANADIAN INTERNATIONAL PHARMACY ASSOCIATION", 2014, "second_quarter", "PHA", "Monitoring Drug importation legislation\nFY 15 Agriculture Appropriations Bill", "HOUSE OF REPRESENTATIVES,SENATE", 20000, null, 0, 0, "2014-07-02T09:05:12.983000-04:00"], [1545812, "a33a19f4-9fe1-41db-8f56-345da0c8904d", "Q2", "INJURED WORKERS PHARMACY", 400765309, "INJURED WORKERS PHARMACY", 2014, "second_quarter", "PHA", "n/a", "HOUSE OF REPRESENTATIVES,SENATE", null, null, 0, 0, "2014-07-02T11:51:42.200000-04:00"], [1545835, "65a2174b-c80e-49ae-a089-d2cb12af6016", "Q2", "CHAMBER HILL STRATEGIES", 400645947, "AMAG PHARMACEUTICALS (FORMERLY KNOWN AS LUMARA PHARMACEUTICAL)", 2014, "second_quarter", "PHA", "Implementation issues related to P.L. 113-54, the Drug Quality and Security Act", "Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2014-07-02T13:00:18.497000-04:00"], [1546092, "abdd4201-a325-4274-8379-efc95603e7ce", "Q2", "GOVBIZ ADVANTAGE, INC.", 294234, "CATALYST HEALTH SOLUTIONS (CATAMARANRX)", 2014, "second_quarter", "PHA", "Monitor Pharmacy Benefit Issues; select state delegation outreach", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2014-07-03T14:55:36.113000-04:00"], [1546102, "b55119be-ff56-49ed-809e-0f6190659492", "Q2", "GOVBIZ ADVANTAGE, INC.", 294234, "WHITE HOUSE CONSULTING (FOR SYMBIOMIX)", 2014, "second_quarter", "PHA", "Womens health issues and GAIN Act implementation issues", "HOUSE OF REPRESENTATIVES,SENATE", 10000, null, 0, 0, "2014-07-03T15:20:43.307000-04:00"], [1546313, "24b1f6af-6bda-42b8-911d-3f58c014f2dc", "Q2", "RED+BLUE STRATEGIES", 400693064, "BLUE CROSS BLUE SHIELD OF MASSACHUSETTS", 2014, "second_quarter", "PHA", "Issues related to opioid abuse interventions and policies to help curb fraud and abuse, while at the same time improving outcomes for  \nindividuals with pain management needs.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2014-07-07T11:35:30.300000-04:00"], [1546516, "cf181ad3-9e3c-4fde-b44d-3554ff1d2ae6", "Q2", "UNIVERSITY OF IOWA", 49191, "UNIVERSITY OF IOWA", 2014, "second_quarter", "PHA", "Increased appropriations for systems to shorten the time between development of a drug and its release to the public\nFDA reform as it relates to drug development and research         \nCollaborative research on drug development                                \nHuman factors research related to neuropharmaceuticals", "Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Federal Emergency Management Agency (FEMA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,Transportation, Dept of (DOT)", null, 85562, 0, 0, "2014-07-07T14:28:39.173000-04:00"], [1546583, "0354785d-fe5d-46b7-8a16-220ad90c3912", "Q2", "RED+BLUE STRATEGIES", 400693064, "EXPRESS SCRIPTS INC.", 2014, "second_quarter", "PHA", "H.R. 1367 - FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act - focused on policies that would negatively impact access to mail order pharmacy\n\nRules, regulations and guidance specific to prescription drug pricing, generic utilization and specialty pharmacy.Issues impacting PBMs in up coming health related legislation.\n\nPolicies related to stopping the diversion of prescription medications in the nation's drug supply chain.\n\nChanges in International Naming policies for generic medications.\n\nACA-related regulations impacting new rules for Exchanges specific to the promulgation of the prescription drug benefits.\n\nIssues regarding prescription drug coverage for DoD\n\nIssues related to Part D coverage for Medicare Beneficiaries in Hospice Care.", "Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2014-07-07T16:20:17.773000-04:00"], [1546591, "4000100e-f835-4ad3-b5d9-a00666e5a8ed", "Q2", "MR. THEODORE (TED) JONES", 20926, "COQUI RADIOPHARMACEUTICALS, CORP.", 2014, "second_quarter", "PHA", "American Medical Isotopes Production Act of 2012 that was contained in the National Defense Authorization Act for Fiscal Year 2013.  Acceleration of production on 99 MO using LEU (Low Enriched Uranium).", "HOUSE OF REPRESENTATIVES,SENATE", 10000, null, 0, 0, "2014-07-07T16:30:20.033000-04:00"], [1546599, "127570d9-1662-4eaa-ad4e-bd1dcbe27fee", "Q2", "HANCE SCARBOROUGH", 17443, "ALLIANCE OF INDEPENDENT PHARMACISTS - TEXAS", 2014, "second_quarter", "PHA", "Federal legislation affecting the practice of pharmacy, and FDA and DEA  regulations of compounded drugs.", "HOUSE OF REPRESENTATIVES,SENATE", 10000, null, 0, 0, "2014-07-07T17:22:26.387000-04:00"], [1546622, "0c3f9a4b-8457-42da-9ad1-872e10656788", "Q2", "MR. JOHN COSTER", 401103305, "AMERISOURCE BERGEN", 2014, "second_quarter", "PHA", "H.R. 4709, Ensuring Patient Access and Effective Drug Enforcement Act of 2014; H.R. 800, S. 806, Excluding Customary Prompt Pay Discounts from ASP in calculating Medicare Part B", null, 10000, null, 0, 0, "2014-07-07T22:28:22.473000-04:00"], [1546823, "f03ee5d1-e6d8-4ebd-8756-81e41c340c05", "2A", "COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE", 11003, "COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE", 2014, "second_quarter", "PHA", "H.R. 4577, Ensuring Seniors Access to Local Pharmacies Act of 2014, all sections", "HOUSE OF REPRESENTATIVES,SENATE", null, 40000, 0, 0, "2014-07-08T12:38:10.107000-04:00"], [1547008, "f6104c3b-43e6-46db-a54a-5353cae18279", "Q2", "CAPITOL HILL CONSULTING GROUP", 72053, "WELLNESS PHARMACY", 2014, "second_quarter", "PHA", "Pharmaceutical Compounding and Accountability Act (S.959)\nThe Compound Clarity Act (HR 3089)\nThe Drug Quality and Security Act (HR 3204)\nIssues related to implementation of the Compounding Quality Act", "HOUSE OF REPRESENTATIVES,SENATE", 10000, null, 0, 0, "2014-07-08T16:19:28.337000-04:00"], [1547010, "2cefd209-9f33-4cf4-a39d-ac7a8f2ffbf4", "Q2", "CAPITOL HILL CONSULTING GROUP", 72053, "ROCK & ASSOCIATES", 2014, "second_quarter", "PHA", "Pharmaceutical Compounding and Accountability Act (S.959)\nThe Compound Clarity Act (HR 3089)\nThe Drug Quality and Security Act (HR 3204)\nIssues related to implementation of the Compounding Quality Act", "HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2014-07-08T16:24:29.663000-04:00"], [1547017, "a8fdbd38-28f6-4f37-9d77-9294a9b30102", "Q2", "CAPITOL HILL CONSULTING GROUP", 72053, "PROFESSIONAL COMPOUNDING CENTERS OF AMERICA", 2014, "second_quarter", "PHA", "Pharmaceutical Compounding and Accountability Act (S.959)\nThe Compound Clarity Act (HR 3089)\nThe Drug Quality and Security Act (HR 3204)\nIssues related to implementation of the Compounding Quality Act", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2014-07-08T16:37:33.203000-04:00"], [1547036, "b7fe7be0-7c25-42f3-94e6-cc8b9a7146b4", "Q2", "CAPITOL HILL CONSULTING GROUP", 72053, "PURDUE PHARMA LLP", 2014, "second_quarter", "PHA", "Controlled Drug Substances Act (21 USC 13)\nStop Tampering of Prescription Pills Act of 2013 (H.R. 486)", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2014-07-08T16:53:38.713000-04:00"], [1547136, "6bc802a2-3f48-4814-94e0-08588d565a2c", "Q2", "MR. JOHN COSTER", 401103305, "AMERICAN SOCIETY OF HEALTH SYSTEM PHARMACISTS", 2014, "second_quarter", "PHA", "Pharmacy Provider Status issues, particularly H.R. 4190, Medicare Coverage of Pharmacy Services", null, null, null, 0, 0, "2014-07-09T07:31:38.353000-04:00"], [1547193, "37403ab7-d02c-4bf6-82eb-5262fbd2e5c7", "Q2", "MR. VINCENT A. PANVINI", 401008845, "PHRMA", 2014, "second_quarter", "PHA", "Transpacific Partnership, Patent Reform Bill", "HOUSE OF REPRESENTATIVES,SENATE", 6000, null, 0, 0, "2014-07-09T10:03:43.890000-04:00"], [1547370, "e4d5f5ca-3b99-4ae9-a7d7-a611ee263a70", "2T", "SQUIRE PATTON BOGGS", 30906, "RANBAXY INC.", 2014, "second_quarter", "PHA", "S. 214, Preserve Access to Affordable Generics; Implementation of P.L. 111-148, Patient Protection & Affordable Care Act; Prescription Drug User Fee Reauthorization issues; S. 959 Pharmaceutical Compounding Quality and Accountability Act; S. 957, Drug Supply Chain Security Act; H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013; H.R. 2186, Verifying Authority and Legality In Drug Compounding Act of 2013.", "HOUSE OF REPRESENTATIVES,SENATE", 120000, null, 0, 1, "2014-07-09T13:49:04.537000-04:00"], [1547409, "72a7843e-fb42-461c-89de-0448c6f9fac7", "Q2", "ABRAHAM & ROETZEL, LLC", 400954757, "MATCHRX", 2014, "second_quarter", "PHA", "Drug Quality and Security Act.", "Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE", 10000, null, 0, 0, "2014-07-09T14:26:21.553000-04:00"], [1547449, "5d58ccaf-b364-44e9-a6f5-6663deeebc1b", "Q2", "KATE MOSS", 25988, "CVS HEALTH", 2014, "second_quarter", "PHA", "Issues related to prescription drug abuse and drug supply chain safety.", "HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2014-07-09T15:29:05.340000-04:00"], [1547519, "a053668b-7c72-430a-9dc5-46e515a03fcd", "Q2", "SANOFI US SERVICES INC.", 56838, "SANOFI US SERVICES INC", 2014, "second_quarter", "PHA", "General issues related to the 340B Federal Drug Pricing Program", "HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE", null, 720000, 0, 0, "2014-07-09T17:05:11.757000-04:00"], [1547664, "f2f9add9-5437-49b2-801a-621be58343a6", "Q2", "THE MATHIS HARPLE GROUP", 322911, "PILMA", 2014, "second_quarter", "PHA", "Patent Reform Legislation, Transpacific Partnership, Intellectual Property", "HOUSE OF REPRESENTATIVES,SENATE", 22500, null, 0, 0, "2014-07-10T11:12:50.473000-04:00"], [1548006, "0472fea7-06f4-47d8-a747-ecd3d2c6c509", "Q2", "ROCK & ASSOCIATES", 33545, "BRAIDWOOD MANAGEMENT, INC.", 2014, "second_quarter", "PHA", "Legislation affecting the operation compounding pharmacies and the availability of compounded medications.  No specific legislation yet.", "HOUSE OF REPRESENTATIVES,SENATE", 11250, null, 0, 0, "2014-07-10T16:51:03.713000-04:00"], [1548202, "fe6b5ecc-dfcd-41ee-bbd1-d6f9c6188aca", "Q2", "MR. JOHN COSTER", 401103305, "HORIZON GOVERNMENT AFFAIRS", 2014, "second_quarter", "PHA", "medication therapy management legislation, HR 1024, S. 557", null, 5000, null, 0, 0, "2014-07-10T20:00:13.813000-04:00"], [1548289, "bf5a2166-d07b-4b22-ab93-b7dfb728574a", "Q2", "DICKSTEIN SHAPIRO LLP", 12208, "VERIMED, LLC", 2014, "second_quarter", "PHA", "Monitor legislative and administrative action regarding prescription drug abuse and diversion policies. \nH.R. 4486, Military Construction Veterans Affairs and Related Agencies Appropriations Act, 2015.\nDraft, Senate Military Construction Veterans Affairs and Related Agencies  Appropriations Act, 2015.\nS. 2450, Veterans' Access to Care through Choice, Accountability, and Transparency Act of 2014.", "Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA)", 60000, null, 0, 0, "2014-07-10T23:05:28.883000-04:00"], [1548444, "98aeaca6-c45c-439a-bd48-0120f85898f4", "Q2", "VALENTE & ASSOCIATES", 45983, "SAV-MOR FRANCHISING, INC.", 2014, "second_quarter", "PHA", "Medicare Part D", "HOUSE OF REPRESENTATIVES", null, null, 0, 0, "2014-07-11T10:01:34.217000-04:00"], [1548896, "c47d5500-afee-49ff-a410-5ed7be5841f7", "Q2", "CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.", 8511, "THE HEMOPHILIA ALLIANCE", 2014, "second_quarter", "PHA", "Issues related to the 340B drug discount program.", "Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2014-07-11T14:51:11.887000-04:00"], [1548908, "c8f0c9ac-a393-4b93-aced-fa35635e3799", "Q2", "CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.", 8511, "AMERICAN SOCIETY OF HEMATOLOGY", 2014, "second_quarter", "PHA", "HR 460 Patient Access to Treatment Act; HR 1801 Cancer Drug Coverage Parity Act/S 1879 Cancer Treatment Parity Act.", "Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE", 30000, null, 0, 0, "2014-07-11T14:58:19.353000-04:00"], [1548923, "6b4e13a8-8de4-4d04-86f8-3ea3b67281b0", "Q2", "CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.", 8511, "NATIONAL HEMOPHILIA FOUNDATION", 2014, "second_quarter", "PHA", "Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing program.\nHR 460 Patients Access to Treatment Act", "Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE", 50000, null, 0, 0, "2014-07-11T15:08:25.037000-04:00"], [1548938, "c22c0b87-127f-4395-ae2a-5fba06c6dfc8", "Q2", "DELAHUNT GROUP, LLC", 401066001, "HEALIANCE PHARMACEUTICALS", 2014, "second_quarter", "PHA", "Issues related to issuance of supplemental OFAC license.", "HOUSE OF REPRESENTATIVES,Natl Security Agency (NSA),SENATE,State, Dept of (DOS)", 50000, null, 0, 0, "2014-07-11T15:16:22.223000-04:00"], [1549016, "14af9727-2824-4e38-89a6-ed06a53b7597", "Q2", "CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.", 8511, "NATIONAL ASSOCIATION OF EPILEPSY CENTERS", 2014, "second_quarter", "PHA", "Issues related to anti-epileptic drugs.", "Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE", 10000, null, 0, 0, "2014-07-11T16:06:52.390000-04:00"], [1549101, "e0150226-eaee-483f-bc9d-c433c7141846", "Q2", "PARRY, ROMANI, DECONCINI & SYMMS", 30792, "POZEN, INC.", 2014, "second_quarter", "PHA", "Support H.R. 2985 - The Combination Drug Development Incentive Act of 2013, to provide incentives for new drug development.", "HOUSE OF REPRESENTATIVES,SENATE", 36000, null, 0, 0, "2014-07-11T17:10:25.350000-04:00"], [1549602, "723885b5-08bf-4e80-b772-febd0cce0327", "Q2", "PD FRAZER CONSULTING, INC.", 65998, "CANADA INTERNATIONAL PHARMACY ASSOCIATION", 2014, "second_quarter", "PHA", "Monitor the development of proposed bills about the importation of prescription drugs.", "HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2014-07-14T11:37:22.750000-04:00"], [1549616, "f3aede7a-cca7-46b8-95c3-38df79cda916", "Q2", "RUBICON ADVISORS, LLC", 315091, "STATE MUTUAL INSURANCE COMPANY", 2014, "second_quarter", "PHA", "Pharmacy - Compounding", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2014-07-14T11:40:03.873000-04:00"], [1549665, "bdfa6312-8440-43a6-bff6-670718121b3a", "Q2", "RUBICON ADVISORS, LLC", 315091, "BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.", 2014, "second_quarter", "PHA", "Physician Payment Sunshine Act S 2029\nPatent Settlements H.R. 14328 .316\nAffordable Healthcare Choices Act", "HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2014-07-14T11:49:17.497000-04:00"], [1549675, "20ae17bb-8a88-4cfb-903d-fe5410a16809", "Q2", "RUBICON ADVISORS, LLC", 315091, "DYNAVAX TECHNOLOGIES", 2014, "second_quarter", "PHA", "Food and Drug Administration - Vaccines", "Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE", 20000, null, 0, 0, "2014-07-14T11:54:23.497000-04:00"], [1549688, "ab416d5e-934a-4e51-b109-eb386d87eaf5", "Q2", "RUBICON ADVISORS, LLC", 315091, "TEVA PHARMACEUTICALS USA", 2014, "second_quarter", "PHA", "Patent Settlements H.R. 1432, Generic Biologies S H.R. 1695, H.R. 5629, Physican Payment Sunshine Act S 2029, Patent Reform H.R. 1908, Import Safety Act H.R. 3100\nAffodable Health Choices Act", "HOUSE OF REPRESENTATIVES,SENATE", 105000, null, 0, 0, "2014-07-14T11:59:26.590000-04:00"], [1549693, "c4fe49e1-44b1-4b76-a4e8-ca1e30d99c34", "Q2", "RUBICON ADVISORS, LLC", 315091, "ALLIANCE TO PREVENT THE ABUSE OF MEDICINES", 2014, "second_quarter", "PHA", "Prescription Drug Abuse Police", "HOUSE OF REPRESENTATIVES,SENATE", 52500, null, 0, 0, "2014-07-14T12:04:28.137000-04:00"], [1550411, "e34a05e1-77ac-4ce5-b17b-6ff506fc423e", "Q2", "HEARTLAND SOLUTIONS GROUP, INC.", 312133, "ZEBRA TECHNOLOGIES CORPORATION", 2014, "second_quarter", "PHA", "Any and all issues related to labeling of generic drugs.", "HOUSE OF REPRESENTATIVES,SENATE", 8950, null, 0, 0, "2014-07-14T16:48:11.947000-04:00"], [1550521, "674f3827-481a-4085-8bf6-36ec72dcd98e", "Q2", "GENENTECH, INC", 15920, "GENENTECH INC", 2014, "second_quarter", "PHA", "Monitor Drug Safety and pedigree legislation.  Monitor legislation and oversight on compounding pharmacies, 340(b) Drug Discount Program, Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to FDA approval of follow-on biologics and length of data exclusivity period, 340B drug pricing program, structure of the Medicare presciption drug benefit.  Public Law 111-152, the Health Care and Education Reconciliation Act of 2010- Implementation issues related to Medicare and Medicaid reimbursement, fees assessed on the pharmaceutical industry, design and structure of the Medicare prescription drug benefit.  Public Law 112-144, the Food and Drug Administration Safety and Innovation Act - legislation related to reauthorization of user fees for prescription drug, medical device, and biologics approval.  All aspects.  General issues and congressional oversight related to FDA approval and CMS coverage decisions regarding Avastin and Lucentis.  S. 959 - Pharmaceutical Quality, Security, and Accountability Act- legislation regarding pharmacy compounding and track and trace proposals.  Public Law 113-67, Continuing Appropriations Resolution for 2014 - General public health spending.  Public law 113-54- The Drug quality and Security Act - drug compounding and track trace issues.", "HOUSE OF REPRESENTATIVES,SENATE", null, 836600, 0, 0, "2014-07-14T18:24:49.397000-04:00"], [1550724, "a88fec84-4c3c-407b-ab42-1377c02f06bb", "Q2", "SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING", 35968, "SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING", 2014, "second_quarter", "PHA", "Pharmacy compounding of radiopharmaceuticals; The Drug Quality and Security Act (HR 3204).", "Centers For Medicare and Medicaid Services (CMS),Energy, Dept of,Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Nuclear Regulatory Commission (NRC),Office of Science & Technology Policy (OSTP),SENATE", null, 80000, 0, 0, "2014-07-15T09:34:04.703000-04:00"], [1550824, "567528b8-976a-4802-97ba-695902c7cb77", "Q2", "ROCK & ASSOCIATES", 33545, "CAPITOL HILL CONSULTING GROUP (ON BEHALF OF WELLNESS PHARMACY)", 2014, "second_quarter", "PHA", "Legislation affecting the operation of compounding pharmacies and the availability of compounded medications.  No specific legislation yet.", "HOUSE OF REPRESENTATIVES,SENATE", null, null, 0, 0, "2014-07-15T10:43:25.483000-04:00"], [1550851, "de516c51-3778-46b9-b8da-2a26426197e3", "Q2", "ROCK & ASSOCIATES", 33545, "DIAMONDBACK DRUGS", 2014, "second_quarter", "PHA", "Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet.", "HOUSE OF REPRESENTATIVES,SENATE", 11250, null, 0, 0, "2014-07-15T10:54:30.217000-04:00"], [1550863, "4f58614e-9961-47dc-9755-25fd0a05b5c5", "Q2", "FLYNN & ASSOCIATES, INC.", 15020, "PHARMACEUTICAL INDUSTRY LABOR-MANAGEMENT ASSOCIATION", 2014, "second_quarter", "PHA", "Medicare Part-D Rebates", "HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2014-07-15T11:03:33.020000-04:00"], [1550876, "5aaac151-1086-41c0-b5bc-3b70b350d386", "Q2", "FLYNN & ASSOCIATES, INC.", 15020, "AMERICAN CHEMISTRY COUNCIL, INC.", 2014, "second_quarter", "PHA", "TSCA Reform \nS.1009", "HOUSE OF REPRESENTATIVES,SENATE", 20000, null, 0, 0, "2014-07-15T11:07:36.957000-04:00"], [1550878, "9f90eb50-677e-4d79-aee3-47f3f493ff3c", "Q2", "ROCK & ASSOCIATES", 33545, "US COMPOUNDING", 2014, "second_quarter", "PHA", "Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet.", "HOUSE OF REPRESENTATIVES,SENATE", 11250, null, 0, 0, "2014-07-15T11:08:38.283000-04:00"], [1550899, "9481beff-d89e-4f56-8987-6c21bf8fb813", "Q2", "ROCK & ASSOCIATES", 33545, "VETERINARY PHARMACIES OF AMERICA, INC.", 2014, "second_quarter", "PHA", "Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet.", "HOUSE OF REPRESENTATIVES,SENATE", 11250, null, 0, 0, "2014-07-15T11:18:44.160000-04:00"], [1550920, "b2d741c2-89cb-4022-a174-50d9a4f319f4", "Q2", "ROCK & ASSOCIATES", 33545, "WEDGEWOOD VILLAGE PHARMACY, INC.", 2014, "second_quarter", "PHA", "Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet.", "HOUSE OF REPRESENTATIVES,SENATE", 11250, null, 0, 0, "2014-07-15T11:27:48.083000-04:00"], [1550931, "4d8779c4-6bb5-480b-bfef-d4bc4f4d6f33", "Q2", "ROCK & ASSOCIATES", 33545, "WOMEN'S INTERNATIONAL PHARMACY", 2014, "second_quarter", "PHA", "Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet.", "HOUSE OF REPRESENTATIVES,SENATE", 11250, null, 0, 0, "2014-07-15T11:36:51.330000-04:00"], [1550950, "727fe420-04d3-40e9-833b-5ae215fd1f30", "Q2", "ROCK & ASSOCIATES", 33545, "TOWN & COUNTRY COMPOUNDING AND CONSULTING", 2014, "second_quarter", "PHA", "Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet.", "HOUSE OF REPRESENTATIVES,SENATE", null, null, 0, 0, "2014-07-15T11:46:58.127000-04:00"], [1551215, "46d8830d-4399-4ff4-9813-6d09e2687be3", "Q2", "THE DUBERSTEIN GROUP INC.", 12675, "PFIZER INC.", 2014, "second_quarter", "PHA", "Agriculture appropriations re drug reimportation - HR 4800, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2015; S 2389, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2015.", "HOUSE OF REPRESENTATIVES,SENATE", 100000, null, 0, 0, "2014-07-15T14:17:24.870000-04:00"], [1551290, "5b130c9b-7398-466b-bde6-7a691f51f1bf", "Q2", "BRAVO GROUP", 296293, "PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA", 2014, "second_quarter", "PHA", "Biopharmaceutical issues including:  social and economic value of the biopharmaceutical sector, patient access and safety issues, life science innovation and job impact.", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2014-07-15T14:50:47.760000-04:00"], [1551297, "10cbfe31-0213-4615-be7f-b28600233df9", "Q2", "RED+BLUE STRATEGIES", 400693064, "PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA)", 2014, "second_quarter", "PHA", "H.R. 1367 - FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act  - focused on policies that would negative impact peoples access to prescription medications through mail.\n\nIssues related to the practice of giving coupons for certain prescription medications.CMS call letter focused on changes in policies regarding mail order and pharmacy networks.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2014-07-15T14:52:48.620000-04:00"], [1551324, "408ebeea-7e0d-4263-b89f-6e356757ba07", "Q2", "RED+BLUE STRATEGIES", 400693064, "PEW CHARITABLE TRUSTS", 2014, "second_quarter", "PHA", "Issues related to continuing to increase the supply of new and innovative antibiotics that will help to treat the myriad antibiotic resistant strains of bugs like MRSA.\nH.R. 3742 - Antibiotic Development to Advance Patient Treatment Act - focused on reinvigorating the pipeline for new antibiotics.Issues related to prescription drug abuse in the Medicare and Medicaid programs.", "Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2014-07-15T15:03:58.377000-04:00"], [1551857, "0fcf7199-9590-4959-baed-84fd56e0dbb7", "Q2", "MR. GALEN RESER", 401055978, "PERRIGO INC (THROUGH FTI GOVERNMENT AFFAIRS)", 2014, "second_quarter", "PHA", "Repeals a requirement enacted into law as part of the PPACA of 2010 that requires consumers to obtain a prescription in order to utilize their FSA's and HSA's to purchase over-the-counter OTC medicines, H.R. 2835, \"Restoring Access to Medication Act of 2013.\" FDA's proposed changes to generic drug labeling. FDA's proposed Infant Formula regulations.", "HOUSE OF REPRESENTATIVES,SENATE", 10000, null, 0, 0, "2014-07-15T17:47:51.267000-04:00"], [1551984, "cc11589a-a6e9-41f7-91c5-8a84aa15ba4c", "Q2", "OREGON HEALTH & SCIENCE UNIVERSITY", 30291, "OREGON HEALTH & SCIENCE UNIVERSITY", 2014, "second_quarter", "PHA", "340b Drug Discount Program for safety net hospitals", "Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE", null, 70000, 0, 0, "2014-07-15T21:17:04.537000-04:00"], [1552342, "4f9c1771-e5d4-4811-8af9-28c036120613", "Q2", "BLUECROSS BLUESHIELD OF TENNESSEE", 6440, "BLUECROSS BLUESHIELD OF TENNESSEE", 2014, "second_quarter", "PHA", "General Pharmacy Issues", "HOUSE OF REPRESENTATIVES,SENATE", null, 40000, 0, 0, "2014-07-16T10:39:22.580000-04:00"], [1552582, "1ade9b5c-7aa7-42e4-9171-7316ad2ca7f1", "Q2", "NOVO NORDISK INC.", 284790, "NOVO NORDISK INC.", 2014, "second_quarter", "PHA", "HR 3204, S. 959 Drug Quality and Security Act (track and trace supply chain provisions); issues regarding biosimilars; 340B", "Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,U.S. Trade Representative (USTR),Veterans Affairs, Dept of (VA)", null, 440000, 0, 0, "2014-07-16T12:08:28.423000-04:00"], [1552824, "efb665c6-67a8-4b91-bb4b-24ebada1ad86", "Q2", "CHRISTY ELLERBEE CONSULTING, LLC", 401103332, "INDIVIOR, PLC (FKA RECKITT BENCKISER PHARMACEUTICALS, INC.)", 2014, "second_quarter", "PHA", "Educating on Medically assisted treatment (MAT) within the opioid addiction disease space.", "HOUSE OF REPRESENTATIVES", null, null, 0, 0, "2014-07-16T13:17:47.043000-04:00"], [1552835, "c8afa91e-25cf-4b6e-81a1-98e8fdb41028", "Q2", "TAUZIN CONSULTANTS, LLC", 400671007, "PILLGUARD MEDICATION DELIVERY SYSTEMS", 2014, "second_quarter", "PHA", "Building awareness of and support for the PillGuard Medication Delivery System as a tool for medication adherence and prescription drug abuse prevention.", "Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE", null, null, 0, 0, "2014-07-16T13:19:49-04:00"], [1553154, "17ba736e-4dc1-4095-b22d-1ce1853ff98b", "Q2", "ENDO INTERNATIONAL", 40011075, "ENDO INTERNATIONAL", 2014, "second_quarter", "PHA", "Issues related to tamper resistant forumulation of pharmaceutical drugs; Life Sciences Jobs and Investment Act.", "HOUSE OF REPRESENTATIVES,SENATE", null, 210000, 0, 0, "2014-07-16T14:58:50.430000-04:00"], [1553369, "a5916306-6971-4b95-a9eb-a9bb881430e6", "Q2", "KENT & O'CONNOR, INC.", 21426, "INTERNATIONAL WAREHOUSE LOGISTICS ASSOCIATION", 2014, "second_quarter", "PHA", "Legislation and regulations relating to drug safety issues.", "Consumer Product Safety Commission (CPSC),Environmental Protection Agency (EPA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE,Surface Transportation Board (STB),Transportation, Dept of (DOT),Transportation Security Administration (TSA),U.S. Customs & Border Protection", 30000, null, 0, 0, "2014-07-16T15:46:26.230000-04:00"], [1553436, "7ec6f405-fb93-46f4-aebd-153846ba3293", "Q2", "NATIONAL COMMUNITY PHARMACISTS ASSOCIATION", 27478, "NATIONAL COMMUNITY PHARMACISTS ASSOCIATION", 2014, "second_quarter", "PHA", "S.644- The Preventing Abuse of Cough Treatments of Acts of 2013; H.R. 1285- To Amend the Controlled Substance Act to Make Any Substance Containing Hydrocodone a Schedule II Drug; S.621- The Safe Prescribing Act of 2013; H.R. 1024- The Medication Therapy Management Empowerment Act of 2013; H.R. 1188- The Preserving of Hometown Independent Pharmacies Act of 2013; CMS proposed rule on Medicare Part D; H.R. 4709- Ensuring Patient Access and Effective Drug Enforcement Act of 2014;H.R. 4190- To Amend Title XVIII of the Social Security Act to provide for coverage under the Medicare program of pharmacist services; FDAs action on and enforcement of Public Law No: 113-54; H.R.4577 - Ensuring Seniors Access to Local Pharmacies Act of 2014; H.R.4437 - Generic Drug Pricing Fairness Act; S. 1493 - Medicare Efficient Drug Dispensing Act of 2013", "Agency for Healthcare Research & Quality (AHRQ),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),Office of Personnel Management (OPM),SENATE", null, 450000, 0, 0, "2014-07-16T15:59:28.417000-04:00"], [1553617, "f6cc510f-2f5f-4b02-a0ad-8f46c7fa15e0", "Q2", "ANIMAL HEALTH INSTITUTE", 4037, "ANIMAL HEALTH INSTITUTE", 2014, "second_quarter", "PHA", "Issues related to illegal drug manufacturing under the guise of compounding.", "HOUSE OF REPRESENTATIVES,SENATE", null, 30000, 0, 0, "2014-07-16T16:34:25.203000-04:00"], [1553968, "dd90a8a5-2e66-47a7-8724-736ffcc7b216", "Q2", "EXPRESS SCRIPTS, INC.", 294416, "EXPRESS SCRIPTS, INC.", 2014, "second_quarter", "PHA", "Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); specialty pharmacy tiering restrictions (HR 460); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).   General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs.  General issues dealing with regulating pharmacy drug compounding (PDSQ Act);  S. 867 (and versions HR 4437, HR 4577), the Medicare Prescription Drug Program Integrity and Transparency Act.", "Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Executive Office of the President (EOP),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Internal Revenue Service (IRS),Labor, Dept of (DOL),Medicare Payment Advisory Commission (MedPAC),Office of Personnel Management (OPM),SENATE,White House Office", null, 550000, 0, 0, "2014-07-16T18:09:32.257000-04:00"], [1554004, "9066f758-044f-4e67-b60d-40140c585571", "Q2", "VENABLE LLP", 39941, "ENDO PHARMACEUTICALS INC", 2014, "second_quarter", "PHA", "Issues related to bioequivalence and related administrative procedures; issues related to prescription drug abuse; issues related to the labeling of generic drugs; issues related to tamper resistant formulation of pharmaceutical drugs. The Life Sciences Jobs and Investment Act; Issues relating to Medicare Part D rebates; H.R. 486  Stop Tampering of Prescription Pills Act of 2013; H.R. 1919  Safeguarding Americas Pharmaceuticals Act of 2013", "HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2014-07-16T18:13:49.103000-04:00"], [1554931, "6f68f65e-ea6f-4933-ba72-cfa7ae8fe011", "Q2", "ELI LILLY AND COMPANY", 13392, "ELI LILLY AND COMPANY", 2014, "second_quarter", "PHA", "Hospital discounts (HR 3590)", "Agriculture, Dept of (USDA),Commerce, Dept of (DOC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR)", null, 1910000, 0, 0, "2014-07-17T10:59:16.323000-04:00"], [1555484, "41741d4e-b494-46f6-880d-ce69ea2795e2", "Q2", "GREATER NEW YORK HOSPITAL ASSOCIATION", 16830, "GREATER NEW YORK HOSPITAL ASSOCIATION", 2014, "second_quarter", "PHA", "Reducing the costs of pharmaceuticals, medical devices, and supplies for consumers and health care providers, including implementation of the Drug Quality and Security Act (P.L.113-54) and P.L.112-144, medical device pricing and tax issues (including gag clauses), and preserving access to group purchasing organizations (GPOs); 340b HRSA guidance on the GPO exclusion (HRSA Release 2013-1); FDA mobile health guidance and regulatory risk-based framework (FDA-2011-D-0530 and FDA-2014-N-0339); regulations affecting point-of-use care for glucose monitoring systems (FDA-2013-D-1445); ongoing pharmaceutical issues pertaining to drug shortages and significant price increases; pharmaceutical labeling of generic drugs (FDA-2013-N-0500); maximum allowable cost price transparency (CMS-4159-P).", "Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Housing & Urban Development, Dept of (HUD),Internal Revenue Service (IRS),SENATE,White House Office", null, 280000, 0, 0, "2014-07-17T12:06:35.013000-04:00"], [1555489, "dd8b1e9b-1da6-4f35-bee3-867e50782675", "Q2", "WHITMER & WORRALL, LLC", 292892, "PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA)", 2014, "second_quarter", "PHA", "Issues related to monitoring healthcare reform.", "Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,State, Dept of (DOS)", 30000, null, 0, 0, "2014-07-17T12:09:26.750000-04:00"], [1555743, "ace5f46a-af96-4a79-a0ec-65538f9189f5", "Q2", "NATIONAL ASSOCIATION OF CHAIN DRUG STORES", 26672, "NATIONAL ASSOCIATION OF CHAIN DRUG STORES", 2014, "second_quarter", "PHA", "S.644, Preventing Abuse of Cough Treatments Act of 2013\nS. 621, Safe Prescribing Act of 2013\nH.R. 1285, Safe Prescribing Act of 2013\nH.R. 1919 Safeguarding America's Pharmaceuticals Act of 2013\nS 959, Pharmaceutical Compounding Quality and Accountability Act\nS 1277, Combating Prescription Drug Abuse Act\nS.957, Drug Supply Chain Security Act\nH.R.3204 - Drug Quality and Security Act\nH.R. 4437 - Generic Drug Pricing Fairness Act", "Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", null, 640000, 0, 0, "2014-07-17T12:52:06.907000-04:00"], [1555746, "4a2a221a-abbf-4ae1-a0ca-0c8933b48c72", "Q2", "AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS", 3457, "AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS", 2014, "second_quarter", "PHA", "Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act.  Contact concerning HRSA oversight of 340B drug discount program. Communication with the OIG on Compendia . Contact concerning the Drug Quality and Security Act, H.R. 3204, all titles. Communication with the FDA on labeling of generic medications and drugs containing salts. Communication with FTC on biosimilars. Support for H.R. 3742, all titles, theAntibiotic Development to Advance Patient Treatment Act.", "Centers For Medicare and Medicaid Services (CMS),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", null, 250000, 0, 0, "2014-07-17T12:53:33.483000-04:00"], [1555830, "a3cc922f-79ea-409d-a421-8ed011623d70", "Q2", "FTI GOVERNMENT AFFAIRS", 401054971, "AMERICAS HEALTH INSURANCE PLANS (AHIP)", 2014, "second_quarter", "PHA", "H.R. 460, Patients' Access to Treatments Act (McKinley) - cost sharing in a specialty drug tier. H.R. 1367, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act (Lynch) - FEHBP prescription drugs. H.R. 3204, Drug Quality and Security Act (Upton) - drug safety issues. S. 214, Preserve Access to Affordable Generics Act (Klobuchar) - access to generic drugs.", "HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2014-07-17T13:09:25.093000-04:00"], [1555835, "b5d5e7e0-9f40-4d83-86ad-7cc96d48adc4", "Q2", "VORYS ADVISORS, LLC", 400873558, "AMERISOURCEBERGEN CORPORATION", 2014, "second_quarter", "PHA", "Various health care proposals.", "HOUSE OF REPRESENTATIVES", null, null, 0, 0, "2014-07-17T13:09:51.107000-04:00"], [1556009, "c54d20a9-2517-4d76-a6d1-691f6b78da06", "Q2", "HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA)", 28776, "HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA)", 2014, "second_quarter", "PHA", "Rx Pedigree (Public Law 113-54); Prescription Drug Monitoring Programs; Prescription Drug Abuse - General issues related to Rx drug abuse, (S. 348, S. 1277, H.R. 4069, H.R. 4709), Hydrocodone Rescheduling (H.R. 1285, S. 621); Dextromethorphan (S. 644); Drug shortages - Gray Market (H.R. 1958); Counterfeit Drugs; Importation of Prescription Drugs (H.R. 3715)", "Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", null, 233000, 0, 0, "2014-07-17T13:59:05.953000-04:00"], [1556109, "8f22a3f2-d6b6-448a-a55b-0e3ff44c27fe", "Q2", "AMERICAN PHARMACISTS ASSOCIATION", 3071, "AMERICAN PHARMACISTS ASSOCIATION", 2014, "second_quarter", "PHA", "HCR(PL 111-152/111-148); Medicare Part D; Medication Therapy Management; Medicare Part B; reimbursement for pharmacist services; Social Security Act; transitions of care; risk evaluation and mitigation services; prescription drug monitoring program; prescription drug abuse; hydrocodone; track and trace/supply chain; ACOs; immunization; HIT; compounding; Sustainable Growth Rate; FDASIA(PL 112-144); tele-medicine; Medicare fraud, waste and abuse; quality rating; AMP FUL's", "Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE", null, null, 0, 0, "2014-07-17T14:14:10.763000-04:00"], [1556249, "9a81069d-bc55-4bc8-826c-348b57861170", "Q2", "THE DUBERSTEIN GROUP INC.", 12675, "PHRMA INC.", 2014, "second_quarter", "PHA", "Agriculture appropriations re drug reimportation - HR 4800, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2015; S 2389, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2015.", "HOUSE OF REPRESENTATIVES", 100000, null, 0, 0, "2014-07-17T14:38:46.047000-04:00"], [1557489, "7062ac82-9efc-48fb-8a4a-edd6ed660c3b", "Q2", "FTI GOVERNMENT AFFAIRS", 401054971, "PERRIGO, INC.", 2014, "second_quarter", "PHA", "Repeals a requirement enacted into law as part of the PPACA of 2010 that requires consumers to obtain a prescription in order to utilize their FSA's and HSA's to purchase over-the-counter OTC medicines, H.R. 2835, \"Restoring Access to Medication Act of 2013.\" FDA's proposed changes to generic drug labeling. FDA's proposed Infant Formula regulations.", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2014-07-17T16:54:09.997000-04:00"], [1557562, "eb7f2a66-f350-42ec-b943-213b365daf29", "Q2", "TCH GROUP, LLC", 51478, "SANOFI US SERVICES INC (FORMERLY KNOWN AS SANOFI-AVENTIS U S INC )", 2014, "second_quarter", "PHA", "General issues related to the 340B Federal Drug Pricing Program", "HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2014-07-17T17:08:04.153000-04:00"], [1558104, "6d1a8c28-a1b0-4317-9c6a-abb8f2e1155d", "Q2", "APOTEX CORP.", 310973, "APOTEX CORP.", 2014, "second_quarter", "PHA", "FDA proposed rule,Supplemental Applications Proposing Labeling Changes For Approved Drugs And Biological Products, Docket Number FDA-2013-N-0500, provisions relating to generic drug labeling changes;Potential legislation relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing;\n\nProposed FDA rule, \"Electronic Distribution of Prescribing Information for Human Prescription Drugs Including Biological Products,\" RIN: 0910-AG18, provisions relating to the use of electronic package inserts for human pharmaceuticals and biologics;\n\nFederal policy relating to issues affecting the generic drug industry within the House Energy and Commerce Committee's 21st Century Cures initiative, and;\n\nFederal policy relating to International Nonroprietary Names for Biosimilars", "Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE", null, 160000, 0, 0, "2014-07-18T08:28:08.857000-04:00"], [1558133, "df8ccd6d-8d97-4155-bcaa-0c6983bcdfe8", "Q2", "THORSEN FRENCH ADVOCACY LLC", 400599826, "ASTRAZENECA PHARMACEUTICALS LP", 2014, "second_quarter", "PHA", "Issues related to access to pharmaceuticals.", "HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2014-07-18T08:43:15.060000-04:00"], [1558140, "c05aa05b-e284-4fc7-9766-cb833bd8b616", "Q2", "ALKERMES, INC.", 400458235, "ALKERMES, INC.", 2014, "second_quarter", "PHA", "DEA regulatory transparency in controlled substances scheduling person\nDEA regulatory transparency in issuing research licenses and quotas", "HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institute on Alcohol Abuse & Alcoholism (NIAA),Natl Institutes of Health (NIH),Office of Natl Drug Control Policy (NDCP),SENATE", null, 553600, 0, 0, "2014-07-18T08:46:16.857000-04:00"], [1558281, "cdb46562-4d67-4bb1-a15b-1b1055e0b889", "Q2", "AMERICAN VETERINARY MEDICAL ASSOCIATION", 3630, "AMERICAN VETERINARY MEDICAL ASSOCIATION", 2014, "second_quarter", "PHA", "H.R. 1150, Preservation of Antibiotics for Medical Treatment Act\nS. 1256, Preventing Antibiotic Resistance Act, H.R. 1528/S. 1171, Veterinary Medicine Mobility Act, H.R. 4023 Fairness to Pet Owners Act, Animal Compounding, Veterinary Feed Directive\nDiscussions with Congressional staff about DEA regulations impeding practice of veterinary medicine; seeking passage oflegislation to change underlying statute (H.R. 1528)\nDiscussions with Congressional staff, FDA and USDA regarding the use of antimicrobials in food-producing animals, particularly with respect to H.R. 1150, (Preseravtion of Antibiotics for Medical Treatment Act) and S. 1256, (Preventing Antibiotic Resistance Act)\nDiscussions with Congressional staff and FDA expressing the need for compounding of medications for use in animals.\nInquiries to and discussions with Congressional staff and Federal Trade Commission on veterinary pet prescriptions, particularly regarding H.R. 4023, (Fairness to Pet Owners Act)", "Agriculture, Dept of (USDA),HOUSE OF REPRESENTATIVES,SENATE", null, 240000, 0, 0, "2014-07-18T09:47:50.230000-04:00"], [1558405, "4a6a1455-795e-412d-a298-3ffba68518ba", "Q2", "TARPLIN, DOWNS & YOUNG, LLC", 304736, "PHRMA", 2014, "second_quarter", "PHA", "**see addendum pagePL 112-144 - The Food and Drug Administration Safety and Innovation Act, implementation\nS. 10, S. 954 - Agriculture Reform, Food, and Jobs Act of 2013\nH.R. 2186 - Valid Compounding Act\nH.R. 3204  The Drug Quality and Security Act, implementation\nH.R. 2725, S. 1413 - Safety Over Sequester Act, user fee sequester relief\n\n\n***, no specific bill(s), prescription drug importation, import safety, supply chain integrity, Prescription Drug User Fee Act and associated policies, user fee sequester, 21st Century Cures", "Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE", 80000, null, 0, 0, "2014-07-18T10:06:37.667000-04:00"], [1558572, "ddd8851f-f4db-4c22-90be-e0209e43f46b", "Q2", "TARPLIN, DOWNS & YOUNG, LLC", 304736, "HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.)", 2014, "second_quarter", "PHA", "**see addendum pageImportation of prescription drugs (H.R. 3715)\nDrug Shortages and Gray Market (H.R. 1958)\nRx Pedigree (PL 113-54)\nPrescription Drug Monitoring Programs  \nCounterfeit Drugs \nPrescription Drug Abuse - General issues related to Rx drug abuse (S. 348, S. 1277, H.R. 4069, H.R. 4709, S. 2437), Hydrocodone Rescheduling (H.R. 1285, S. 621), Dextromethorphan (S. 644)", "Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE", 80000, null, 0, 0, "2014-07-18T10:22:23.293000-04:00"], [1558682, "5e16ff66-3881-4ad7-9618-822eef19eea8", "Q2", "WILLIAMS AND JENSEN, PLLC", 41454, "PHARMACY SERVICES", 2014, "second_quarter", "PHA", "Regulations of compounding pharmacies.", "HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2014-07-18T10:31:57.747000-04:00"], [1558804, "5c9f9130-5eba-4fc9-ab7e-37870fad0cad", "Q2", "TARPLIN, DOWNS & YOUNG, LLC", 304736, "ASTRAZENECA", 2014, "second_quarter", "PHA", "**see addendum pagePL 112-144 - The Food and Drug Administration Safety and Innovation Act, implementation \nH.R. 2186 - Valid Compounding Act\nH.R. 3204  The Drug Quality and Security Act, implementation\nH.R. 2725, S. 1413 - Safety Over Sequester Act, user fee sequester relief\n\n\n***, no specific bill(s), Import Safety, Prescription Drug User Fee Act renewal, drug development policy, drug shortages, supply chain integrity, patent settlements, user fee sequester relief, 21st Century Cures", "Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2014-07-18T10:47:45.217000-04:00"], [1558843, "00d22196-7dc1-40a2-a9cc-0994a8c59210", "Q2", "TARPLIN, DOWNS & YOUNG, LLC", 304736, "BIOTECHNOLOGY INDUSTRY ORGANIZATION", 2014, "second_quarter", "PHA", "**see addendum pagePL 112-144 - The Food and Drug Administration Safety and Innovation Act, implementation \nH.R. 2186 - Valid Compounding Act\nH.R. 3204  The Drug Quality and Security Act, implementation\nH.R. 2725, S. 1413 - Safety Over Sequester Act, user fee sequester relief \n\n \n***, no specific bill(s), Drug Safety, Prescription Drug Importation, Import Safety, supply chain integrity, biosimilars, PDUFA and associated policies, patent settlements, accelerated approval, break through therapies, compounding, user fee sequester, 21st Century Cures", "Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE", 80000, null, 0, 0, "2014-07-18T10:52:56.557000-04:00"], [1559617, "b67fbab2-87bc-4eb3-ba42-88fe22282461", "Q2", "NAHIGIAN STRATEGIES, LLC", 322897, "TEVA PHARMACEUTICALS USA INC", 2014, "second_quarter", "PHA", "Prescription drug misuse", "HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2014-07-18T11:42:58.230000-04:00"], [1559619, "86752ca1-1c33-4f67-ac00-aa9cb87ee294", "Q2", "MCKENNA, LONG & ALDRIDGE", 76913, "PURDUE PHARMA", 2014, "second_quarter", "PHA", "U.S. and Canadian regulatory policies regarding prescription drug abuse.", "HOUSE OF REPRESENTATIVES,SENATE", 10000, null, 0, 0, "2014-07-18T11:42:59.307000-04:00"], [1559841, "c8211df9-8087-4a23-80cf-3791bf42e47a", "Q2", "EMPIRE CONSULTING GROUP", 400703105, "PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA", 2014, "second_quarter", "PHA", "Issues relating to the Medicare Prescription Drug Act; budgetary issues pertaining to Medicare Part D; issues relating to a report on clinical trials and minority communities; 340B Drug Pricing Program; and possible amendments to agriculture appropriations legislation relating to pharmaceuticals.", "HOUSE OF REPRESENTATIVES", 40000, null, 0, 0, "2014-07-18T12:04:07.887000-04:00"], [1559903, "d85cf3e6-cf75-434c-97fc-3a5882df1869", "Q2", "KOUNTOUPES DENHAM CARR & REID, LLC", 320918, "CONSUMER HEALTHCARE PRODUCTS ASSOCIATION", 2014, "second_quarter", "PHA", "General issues related to over the counter pharmaceuticals, potential legislation to implement real-time, stop-sale electronic track- ing system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient common in popular cold and allergy medications, and opposition to prescription requirements.  FDA Review of the Over the Counter Review Monograph and related rulemaking; H.R.4502 Stop Meth Labs and Enhance Patient Access Act of 2014.", "Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE", 50000, null, 0, 0, "2014-07-18T12:10:29.810000-04:00"], [1560154, "dd2de195-c05b-4189-a3ae-1a5666f3ee71", "Q2", "AMERICAN HORSE COUNCIL", 2560, "AMERICAN HORSE COUNCIL", 2014, "second_quarter", "PHA", "In support of the Veterinary Medicine Mobility Act of 2013 (H.R.1528)", "HOUSE OF REPRESENTATIVES,SENATE", null, 10000, 0, 0, "2014-07-18T12:35:58.577000-04:00"], [1560208, "861201e9-c907-4910-8de8-49c7eeed82fb", "Q2", "BROWN RUDNICK LLP", 287895, "APOTEX CORPORATION", 2014, "second_quarter", "PHA", "Issues relating to Risk Evaluation and Mitigation Strategies; Drug Quality and Security Act ( P.L. 113-54); FDA Proposed Rule on Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products (RIN:0910-AG94).", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2014-07-18T12:44:17.420000-04:00"], [1560281, "de7f2e79-b2da-4730-b1bc-db1d50ffb060", "Q2", "ACADEMY OF MANAGED CARE PHARMACY", 48793, "ACADEMY OF MANAGED CARE PHARMACY", 2014, "second_quarter", "PHA", "Support for legislation (National All Schedules Prescription Electronic Reporting Reauthorization Act of 2013 - NAPSER) to reauthorize the controlled substance monitoring programs under the Public Health Service Act designed to foster the establishment of state-administered prescription drug monitoring programs (S 2529/HR 3528).", "Centers For Medicare and Medicaid Services (CMS),Federal Trade Commission (FTC),HOUSE OF REPRESENTATIVES,SENATE", null, 197000, 0, 0, "2014-07-18T12:52:40.717000-04:00"], [1560286, "70215a43-5d6e-4e3a-ad2c-8f6af03d9485", "Q2", "BROWN RUDNICK LLP", 287895, "HOSPIRA, INC.", 2014, "second_quarter", "PHA", "Issues relating to drug shortages, patent use codes and drug labeling (RIN:0910-AG94: FDA Proposed Rule on Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products)", "HOUSE OF REPRESENTATIVES,SENATE,White House Office", 50000, null, 0, 0, "2014-07-18T12:54:42.920000-04:00"], [1560385, "8ec647c1-28eb-4dd1-b695-72494193384f", "Q2", "BROWN RUDNICK LLP", 287895, "PRIME THERAPEUTICS", 2014, "second_quarter", "PHA", "Issues relating to generic pharmaceutical utilization; HR 4577 - Ensuring Seniors Access to Local Pharmacies Act of 2014", "Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2014-07-18T13:05:14.123000-04:00"], [1560486, "9de452b9-4bcf-4f31-a9cc-87845915a82e", "Q2", "BROWN RUDNICK LLP", 287895, "HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC", 2014, "second_quarter", "PHA", "H.R. 4709 & HR. 4069-Ensuring Patient Access and Effective Drug Enforcement Act\"", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2014-07-18T13:16:36.903000-04:00"], [1560514, "48a728e5-3995-4e02-8d1f-3419e25ae292", "Q2", "BROWN RUDNICK LLP", 287895, "MEDTRONIC INC", 2014, "second_quarter", "PHA", "DEA regulation relating to dispensing of compounded controlled substances to practitioner", "Commerce, Dept of (DOC),HOUSE OF REPRESENTATIVES,SENATE,White House Office", 20000, null, 0, 0, "2014-07-18T13:22:46.610000-04:00"]], "truncated": false, "filtered_table_rows_count": 232, "expanded_columns": [], "expandable_columns": [[{"column": "filing_uuid", "other_table": "lobbying_filings_raw", "other_column": "filing_uuid"}, "registrant_name"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "units": {}, "query": {"sql": "select id, filing_uuid, filing_type, registrant_name, registrant_id, client_name, filing_year, filing_period, issue_code, specific_issues, government_entities, income_amount, expense_amount, is_no_activity, is_termination, received_date from lobbying_activities where \"filing_period\" = :p0 and \"filing_year\" = :p1 and \"issue_code\" = :p2 order by filing_year desc limit 101", "params": {"p0": "second_quarter", "p1": "2014", "p2": "PHA"}}, "facet_results": {"issue_code": {"name": "issue_code", "type": "column", "hideable": false, "toggle_url": "/lobbying/lobbying_activities.json?filing_period=second_quarter&filing_year=2014&issue_code=PHA", "results": [{"value": "PHA", "label": "PHA", "count": 232, "toggle_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_period=second_quarter&filing_year=2014", "selected": true}], "truncated": false}, "filing_year": {"name": "filing_year", "type": "column", "hideable": false, "toggle_url": "/lobbying/lobbying_activities.json?filing_period=second_quarter&filing_year=2014&issue_code=PHA", "results": [{"value": 2014, "label": 2014, "count": 232, "toggle_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_period=second_quarter&issue_code=PHA", "selected": true}], "truncated": false}, "filing_period": {"name": "filing_period", "type": "column", "hideable": false, "toggle_url": "/lobbying/lobbying_activities.json?filing_period=second_quarter&filing_year=2014&issue_code=PHA", "results": [{"value": "second_quarter", "label": "second_quarter", "count": 232, "toggle_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_year=2014&issue_code=PHA", "selected": true}], "truncated": false}}, "suggested_facets": [{"name": "filing_type", "toggle_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_period=second_quarter&filing_year=2014&issue_code=PHA&_facet=filing_type"}, {"name": "income_amount", "toggle_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_period=second_quarter&filing_year=2014&issue_code=PHA&_facet=income_amount"}, {"name": "is_termination", "toggle_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_period=second_quarter&filing_year=2014&issue_code=PHA&_facet=is_termination"}, {"name": "received_date", "type": "date", "toggle_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_period=second_quarter&filing_year=2014&issue_code=PHA&_facet_date=received_date"}], "next": "2014,1560514", "next_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_period=second_quarter&filing_year=2014&issue_code=PHA&_next=2014%2C1560514&_sort_desc=filing_year", "private": false, "allow_execute_sql": true, "query_ms": 2160.9676940133795, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}